Eculizumab therapy in a patient with dense-deposit disease associated with partial lipodystropy

Pediatric Nephrology

Volumn 29, Issue 7, 2014, Pages 1283-1287

  Ozkaya, Ozan ^a   Nalcacioglu, Hulya ^a   Tekcan, Demet ^a   Genc, Gurkan ^a   Meydan, Bilge Can ^a   Ozdemir, B Handan ^b   Baysal, M Kemal ^a   Keceligil, Hasan Tahsin ^a  

^a ONDOKUZ MAYIS UNIVERSITY   (Turkey)

^b BASKENT UNIVERSITY   (Turkey)

Author keywords

C3 nephritic factor; Complement alternative pathway; Dense deposit disease; Eculizumab

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; COMPLEMENT FACTOR H; CREATININE; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; ECULIZUMAB; ENOXAPARIN; FRESH FROZEN PLASMA; FUROSEMIDE; MENINGOCOCCUS VACCINE; METHYLPREDNISOLONE; NEPHRITIC FACTOR; PNEUMOCOCCUS VACCINE; PREDNISONE; COMPLEMENT COMPONENT C3; MONOCLONAL ANTIBODY;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ARM SWELLING; ARTICLE; CASE REPORT; CHEEK ATROPHY; CORTICOSTEROID THERAPY; DENSE DEPOSIT DISEASE; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; EDEMA; EXON; FACE DISORDER; FACIES; FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; GENE MUTATION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; HEART ATRIUM THROMBOSIS; HEART SURGERY; HEMOLYTIC UREMIC SYNDROME; HETEROZYGOTE; HUMAN; HYPOALBUMINEMIA; IMMUNOFLUORESCENCE MICROSCOPY; KIDNEY BIOPSY; KIDNEY FUNCTION; LEUKOPENIA; LIPODYSTROPHY; MEDICAL HISTORY; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; NEISSERIA MENINGITIDIS; NEPHROTIC RANGE PROTEINURIA; PERIPHERAL EDEMA; PHARYNGITIS; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; RARE DISEASE; STERNOTOMY; STREPTOCOCCUS PNEUMONIAE; SYSTOLIC HYPERTENSION; TREATMENT DURATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLICATION; DEFICIENCY; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; IMMUNOLOGY;

ADOLESCENT; ANTIBODIES, MONOCLONAL, HUMANIZED; COMPLEMENT C3; COMPLEMENT C3 NEPHRITIC FACTOR; COMPLEMENT FACTOR H; COMPLEMENT PATHWAY, ALTERNATIVE; FEMALE; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; HUMANS; LIPODYSTROPHY;

EID: 84901672159     PISSN: 0931041X     EISSN: 1432198X     Source Type: Journal    
DOI: 10.1007/s00467-013-2748-5     Document Type: Article

References (15)

1. Appel GB, Cook HT, Hageman G, Jennette JC, Kashgarian M, Kirschfink M, Lambris JD, Lanning L, Lutz HU, Meri S, Rose NR, Salant DJ, Sethi S, Smith RJ, SmoyerW, Tully HF, Tully SP, Walker P, Welsh M, Würzner R, Zipfel PF (2005) Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol 16:1392-1403 (Pubitemid 41716523)
2. Nester CM, Smith RJ (2013) Treatment options for C3 glomerulopathy. Curr Opin Nephrol Hypertens 22:231-237
3. Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V, French Study Group for aHUS/C3G (2012) Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies.Nat Rev Nephrol 8:643-657
4. Donadio JV Jr, Offord KP (1989) Reassessment of treatment results in membranoproliferative glomerulonephritis, with emphasis on life-table analysis. Am J Kidney Dis 14:445-451 (Pubitemid 20057890)
5. McCaughan JA, O'Rourke DM, Courtney AE (2012) Recurrent dense deposit disease after renal transplantation: an emerging role for complementary therapies. Am J Transplant 12:1046-1051
6. Daina E, Noris M, Remuzzi G (2012) Eculizumab in a patient with dense-deposit disease. N Engl J Med 366:1161-1163
7. Bomback AS, Smith RJ, Barile GR, Zhang Y, Heher EC, Herlitz L, Stokes MB, Markowitz GS, D'Agati VD, Canetta PA, Radhakrishnan J, Appel GB (2012) Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol 7:748-756
8. Vivarelli M, Pasini A, Emma F (2012) Eculizumab for the treatment of dense-deposit disease. N Engl J Med 366:1163-1165
9. Fakhouri F, Fremeaux-Bacchi V, Noel LH, Cook HT, Pickering MC (2010) C3 glomerulopathy: a new classification. Nat Rev Nephrol 6:494-499
10. Sethi S, Fervenza FC (2012) Membranoproliferative glomerulonephritis - a new look at an old entity. N Engl J Med 366:1119-1131
11. Misra A, Pethambaram A, Garg A (2004) Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and review of the literature. Medicine 83:18-34 (Pubitemid 38124853)
12. Zhang Y, Meyer NC, Wang K, Nishimura C, Frees K, Jones M, Katz LM, Sethi S, Smith RJ (2012) Causes of alternative pathway dysregulation in dense deposit disease. Clin J Am Soc Nephrol 7:265-674
13. Abrera-Abeleda MA, Nishimura C, Frees K, Jones M, Maga T, Katz LM, Zhang Y, Smith RJ (2011) Allelic variants of complement genes associated with dense deposit disease. J Am Soc Nephrol 22:1551-1559
14. Rabasco-Ruiz C, Huerta-Arroyo A, Caro-Espada J, Gutiérrez- Martínez E, Praga-Terente M (2013) C3 Glomerulopathies. A new perspective on glomerular diseases. Nefrologia 33:164-170
15. Krmar RT, Holtbäck U, Linné T, Berg UB, Celsi G, Söderberg MP, Wernerson A, Szakos A, Larsson S, Skattum L, Bárány P (2011) Acute renal failure in dense deposit disease: complete recovery after combination therapy with immunosuppressant and plasma exchange. Clin Nephrol 75:4-10